Similarly, the down-regulation of CD81 surface expression with a combination of the histone deacetylase inhibitor panobinostat and the DNA-hypomethylating agent azacytidine was found to promote ALL cell mobilization from bone marrow to peripheral blood, thereby increasing the response to chemotherapy in disseminated patient-derived xenograft models [23]. Here, CD81 is linked to acute lymphoblastic leukemia.